ATAI Life Sciences (ATAI) was downgraded to a Hold Rating at Maxim Group

ATAI Life Sciences (ATAIResearch Report) received a Hold rating and price target from Maxim Group analyst Michael Okunewitch yesterday. The company’s shares closed yesterday at $1.82.

Okunewitch covers the Healthcare sector, focusing on stocks such as Mediwound, Kiora Pharmaceuticals, and Citius Pharmaceuticals. According to TipRanks, Okunewitch has an average return of -29.2% and a 15.15% success rate on recommended stocks.

Currently, the analyst consensus on ATAI Life Sciences is a Strong Buy with an average price target of $24.50.

See Insiders’ Hot Stocks on TipRanks >>

ATAI market cap is currently $301.9M and has a P/E ratio of -1.46.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine.

Read More on ATAI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed